Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Design Therapeutics Q4 2024 GAAP EPS $(0.24) Beats $(0.28) Estimate

Author: Benzinga Newsdesk | March 10, 2025 07:10am
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.28) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.21) per share from the same period last year.

Posted In: DSGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist